Project Grant R43HL154959

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $618,045 to the University of Arizona to conduct research on identifying new mechanisms and targets for treating early onset diastolic dysfunction in hypertrophic cardiomyopathy (HCM). The research aims to fully characterize three specific functional domains of the cardiac thin filament linked to the regulation of relaxation, determine...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $777,258 to the Beth Israel Deaconess Medical Center, Inc. (Bidmc) to conduct research aimed at improving the understanding and treatment of heart failure in patients with hypertrophic cardiomyopathy (HCM). The key objectives of this research project are to use advanced cardiac imaging techniques, such as cardiac magnetic resonance...

This Project Grant award, valued at $159,512.00, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The funding supports research to uncover effective strategies for mitigating the detrimental effects of cardiac fibrosis, a prominent hallmark of dilated cardiomyopathy (DCM), an inherited heart disease. The key products and services to be delivered include: 1) validating and describing the...

This $601,563 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program supports research to investigate the pathogenic roles and molecular mechanisms of histone lysine demethylases KDM5A and KDM5B in the development and progression of heart failure. The key objectives are to: 1) determine the mechanisms by which deleting KDM5A and KDM5B improves cardiac function and survival in a mouse model of dilated...

This federal Project Grant award from the National Center for Advancing Translational Sciences (NCATS), CFDA 93.350, provides $110,000 to Myogene Bio LLC to conduct preclinical research on the long-term durability of a gene editing therapy for Duchenne muscular dystrophy (DMD). The gene editing therapy is designed to remove DMD exons 45-55 to restore the reading frame for 50% of DMD patients while retaining 87% of the protein coding sequence. The funded studies will assess molecular and...

The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), awarded a $1,358,179 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Revidia Therapeutics, Inc. The award supports the completion of IND-enabling safety and toxicity testing for a subcutaneous formulation of the PTP1B inhibitor MSI-1436, a novel therapeutic approach for treating fatal cardiomyopathy in Duchenne muscular dystrophy patients. Key activities...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $174,050 to investigate the role of the myosin super-relaxed state in contributing to contractile dysfunction in human dilated cardiomyopathy. The central hypothesis is that increased myosins in the super-relaxed state, potentially mediated by depressed regulatory protein phosphorylation, leads to reduced contractile force in...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $171,811 to The Johns Hopkins University to conduct a 5-year research project on the role of skeletal muscle actin mutations in dilated cardiomyopathy (DCM). The research aims to: 1) define the mechanistic basis of how skeletal muscle actin mutations, specifically the R256H mutation, contribute to DCM; and 2) support the principal...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $2,185,454 to Tufts Medical Center to investigate the role of the FHOD3 gene variant in regulating the autophagy pathway and its impact on the development of hypertrophic cardiomyopathy (HCM) and heart failure. The research aims to evaluate the effects of stimulating or inhibiting autophagy in FHOD3 variant mice, as well as assessing...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $653,854 to the University of Pittsburgh to conduct research focused on improving cardiac function and reducing arrhythmia susceptibility in cardiomyopathy patients. The research aims to define how cardiomyocyte-specific modulation of key natriuretic peptide signaling pathways, including PKG1 activity and PIAS1 regulation,...